A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MUK-five
- 04 Dec 2018 Results based on genetic risk and long term follow up of the phase 2 Muk Five trial presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Primary endpoint (Progression-free survival) has been met, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology